Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2013-04-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-12-1162PMID 23619301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regorafenib in metastatic colorectal cancer

  2014influential reference
• A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

  2012cited by this paper
• Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

  2012cited by this paper
• Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

  2012cited by this paper
• Survival from colorectal cancer in Germany in the early 21st century

  2012influential reference
• Efficacy of Tie2 receptor antagonism in angiosarcoma.

  2012cited by this paper
• Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

  2012influential reference
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012influential reference
• Regorafenib in metastatic colorectal cancer.

  2012cited by this paper
• Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

  2012influential reference
• An update on the current and emerging targeted agents in metastatic colorectal cancer.

  2012cited by this paper
• The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

  2011cited by this paper
• TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

  2011cited by this paper
• Impact of KRAS Mutations on Management of Colorectal Carcinoma

  2011cited by this paper
• Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011influential reference
• Treatment of metastatic colorectal cancer.

  2011cited by this paper
• Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis

  2011cited by this paper
• TIE2-expressing myeloid cells as a predictive marker for bevacizumab-containing chemotherapy in metastatic colorectal cancer.

  2011cited by this paper
• Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth

  2011cited by this paper
• Macrophage diversity enhances tumor progression and metastasis.

  2010cited by this paper
• The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.

  2010cited by this paper
• Antiangiogenesis agents in colorectal cancer

  2010cited by this paper
• Targeting the ANGPT–TIE2 pathway in malignancy

  2010cited by this paper
• Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

  2010cited by this paper
• Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.

  2009cited by this paper
• Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

  2009influential reference
• Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

  2009cited by this paper
• Approaches to biomarkers in human colorectal cancer: looking back, to go forward.

  2009cited by this paper
• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  2009cited by this paper
• Novel Agents on the Horizon for Cancer Therapy

  2009cited by this paper
• Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

  2009cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008influential reference
• Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

  2008cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Pericytes: gatekeepers in tumour cell metastasis?

  2008cited by this paper
• Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

  2007cited by this paper
• Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?

  2006cited by this paper
• Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

  2006cited by this paper
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

  2005cited by this paper
• The MAPK signalling pathways and colorectal cancer.

  2005cited by this paper
• Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

  2005cited by this paper
• Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.

  2004cited by this paper
• Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic

  2004cited by this paper
• Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.

  2004cited by this paper
• Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma.

  2004cited by this paper
• It's the poison that killed him, you say!

  2003cited by this paper
• Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

  2002cited by this paper
• Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

  2001cited by this paper
• Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases

  2000cited by this paper
• The prognostic significance of tumor vascularization in patients with localized colorectal cancer

  1999cited by this paper
• Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

  1999cited by this paper
• Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging

  1999cited by this paper
• Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.

  1996cited by this paper
• Invasion and metastasis

  1996cited by this paper
• Microvessel quantification and its possible relation with liver metastasis in colorectal cancer

  1996cited by this paper
• Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.

  1995cited by this paper
• Prognostic significance of K-ras mutations in colorectal carcinoma.

  1993cited by this paper
• Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper

• Assessment of Response to Regorafenib in Patients with Glioma Relapse Using 18F-FET PET and MRI

  2026cites this paper
• Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies.

  2026cites this paper
• Development of a UPLC-MS/MS method and its application for the pharmacokinetic analysis of regorafenib in rats.

  2026cites this paper
• LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer

  2026cites this paper
• Synergistic mechanisms and clinical translation of regorafenib combination therapies.

  2026cites this paper
• Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions

  2025cites this paper
• The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies

  2025cites this paper
• MSP-RON signaling in liver pathobiology and as an emerging therapeutic target: a review of the current evidence

  2025cites this paper
• Optimized Dosing of Regorafenib in Patients With Metastatic Colorectal Cancer: A Practical Guide for Oncologists, Advanced Practice Providers, and Pharmacists.

  2025cites this paper
• The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.

  2025cites this paper
• Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review

  2025cites this paper
• A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma

  2025cites this paper
• AMSC/CXCR4-derived exosomes and miRNA-320 regulate pathological angiogenesis in diabetes

  2025cites this paper
• Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma

  2025cites this paper
• Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis

  2025cites this paper
• Recent Advances in Supramolecular Systems for Precision Medicine: Structural Design, Functional Integration, and Clinical Translation Challenges

  2025cites this paper
• A PD-L1/CD3 BISPECIFIC ANTIBODY ENHANCES THE ANTI-TUMOR EFFECTS OF REGORAFENIB AGAINST COLON CANCER.

  2025cites this paper
• Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma

  2025cites this paper
• Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization

  2024cites this paper
• GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications

  2024cites this paper
• Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.

  2024cites this paper
• The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis

  2024cites this paper
• Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer

  2024cites this paper
• Regorafenib Enhances the Efficacy of Photodynamic Therapy in Hepatocellular carcinoma through MAPK Signaling Pathway Suppression.

  2024cites this paper
• Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma

  2024cites this paper
• Orthotopic and metastatic tumour models in preclinical cancer research

  2024cites this paper
• Design, Synthesis and Evaluation of A Novel Teoptinib Derivative as an Effective Anti-Hepatocellular Carcinoma Agent.

  2024cites this paper
• Advancements in combining targeted therapy and immunotherapy for colorectal cancer.

  2024cites this paper
• What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?

  2024cites this paper
• Downstaging and laparoscopic hepatectomy plus intraoperative radiofrequency ablation for the treatment of initially unresectable multifocal hepatocellular carcinomas

  2024cites this paper
• Small molecule-based targeted therapy in liver cancer.

  2024cites this paper
• Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

  2024cites this paper
• Antimetastatic effect of nanodiamond-conjugated quercetin against colon cancer: an in vivo study

  2024cites this paper
• Chemotherapy combined with regorafenib and immune checkpoint inhibitors as a first-line treatment for patients with advanced biliary tract cancer: a single arm phase II trial

  2024cites this paper
• Regorafenib enhances M1/M2 macrophage polarization by inhibiting the secretion of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.

  2024cites this paper
• Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers.

  2024cites this paper
• TKIs in combination with immunotherapy for hepatocellular carcinoma

  2023cites this paper
• Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders

  2023cites this paper
• Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy

  2023cites this paper
• Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma

  2023cites this paper
• Regorafenib modulation of the angiopoietin/TIE2 axis in a mouse model of sepsis-induced lung injury

  2023cites this paper
• Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center

  2023cites this paper
• A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy

  2023cites this paper
• Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review)

  2023cites this paper
• Experimental Peritoneal Metastasis Model: Which Type of Rodents Should we Choose, and which Method Should we Perform for the Intraperitoneal Inoculation of Tumor Cells?

  2023cites this paper
• Regorafenib induces Bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export

  2023cites this paper
• Impact of age and gender on glioblastoma onset, progression, and management.

  2023cites this paper
• Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy

  2023cites this paper
• Cyclodextrin-Based Arsenal for Anti-Cancer Treatments.

  2023cites this paper
• An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors

  2023influential citation
• A Novel Patient‐Personalized Nanovector Based on Homotypic Recognition and Magnetic Hyperthermia for an Efficient Treatment of Glioblastoma Multiforme

  2023cites this paper
• Immune Cells in the Tumor Microenvironment of Soft Tissue Sarcomas

  2023cites this paper
• Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy

  2023cites this paper
• Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice

  2023cites this paper
• Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma

  2023cites this paper
• Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay

  2023cites this paper
• A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies

  2023cites this paper
• Exploring the anti-metastatic effects of Astragalus mongholicus Bunge-Curcuma aromatica Salisb. on colorectal cancer: A network-based metabolomics and pharmacology approach.

  2023cites this paper
• Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

  2023cites this paper
• Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance

  2023cites this paper
• Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption.

  2023cites this paper
• Development and evaluation of regorafenib loaded liquid suppository for rectal delivery: In vitro, in vivo analyses

  2023cites this paper
• Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer

  2023cites this paper
• Combination of systemic immune-inflammation index and albumin-bilirubin grade predict prognosis of regorafenib in unresectable hepatocellular carcinoma.

  2023cites this paper
• Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

  2022cites this paper
• Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.

  2022cites this paper
• Exploring the Interplay between Metabolism and Tumor Microenvironment Based on Four Major Metabolism Pathways in Colon Adenocarcinoma

  2022cites this paper
• Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas

  2022cites this paper
• Immuntherapie und zielgerichtete Therapie von Gliomen

  2022cites this paper
• Remission of a Primary, Recurrent Thoracic Ewing Sarcoma in a 74-year-old woman

  2022cites this paper
• Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

  2022cites this paper
• 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

  2022cites this paper
• Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer

  2022cites this paper
• 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

  2022cites this paper
• Clinical management of metastatic colorectal cancer in the era of precision medicine

  2022cites this paper
• Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study

  2022cites this paper
• Advances in immunotherapy for MMR proficient colorectal cancer.

  2022cites this paper
• Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer

  2022cites this paper
• Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety

  2022cites this paper
• Modular and mechanistic changes across stages of colorectal cancer

  2022cites this paper
• Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer

  2022cites this paper
• Frontline therapy for advanced hepatocellular carcinoma: an update

  2022cites this paper
• Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice

  2022cites this paper
• Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review

  2022cites this paper
• Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?

  2022cites this paper
• 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

  2022cites this paper
• Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

  2022cites this paper
• Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defense

  2022cites this paper
• Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal Cancer

  2022cites this paper
• Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines

  2022cites this paper
• Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib.

  2022cites this paper
• A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.

  2022cites this paper
• Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives.

  2022cites this paper
• Regorafenib: A narrative drug review

  2022cites this paper
• Regorafenib for the Treatment of Sarcoma

  2022cites this paper
• PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction

  2021cites this paper
• Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

  2021cites this paper
• Management of hepatocellular carcinoma with novel immunotherapeutic agents and prospects for the future

  2021cites this paper
• Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer

  2021cites this paper
• Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency

  2021cites this paper